AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN) today announced that Dr. Julie Shimer, who led Welch Allyn Inc. and Vocera Communications as its Chief Executive Officer and President, has been appointed to Apollo’s Board of Directors by shareholder election on May 23, 2018. Additionally, John Creecy, CEO of Remeditex Ventures, has retired from the Board following a 7-year tenure.
Dr. Shimer will join eight other directors, four of whom are independent under the rules and regulations of the United States Securities and Exchange Commission, and will serve as the board’s Chair of the Compensation Committee.
“Julie is an accomplished business leader and an experienced board member who brings a wealth of executive leadership skills and experience to our board from a variety of industries and settings,” said Rich Meelia, Chairman of Apollo’s Board of Directors. “We are confident that she will add great value to our Board of Directors and that Apollo will benefit from her insights, judgment and counsel.”
In addition to serving as Chief Executive Officer and President, Dr. Shimer served in various other leadership roles, including General Manager at 3Com Corporation and Product Development at Motorola and AT&T Bell Laboratories. Dr. Shimer currently serves on the Board of Directors of Netgear, Halyard Health and Windstream, and previously served on the Board of Directors of Earthlink. Dr. Shimer holds an M.S. and Ph.D. in Electrical Engineering from Lehigh University and a B.S. in Physics from Rensselaer Polytechnic Institute.
Chairman Rich Meelia also stated, “On behalf of the board and the entire management team, I’d like to thank John Creecy for his many contributions and leadership. He has been a valuable member of the board in shaping Apollo’s strategy and vision and we thank him for his service.”
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal conditions. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the ORBERA® Intragastric Balloon, and the LAP-BAND® Adjustable Gastric Banding System.
Apollo’s common stock is traded on Nasdaq Global Market under the symbol "APEN." For more information regarding Apollo, go to: www.apolloendo.com.
© 2018 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: reports of adverse events related to our products, developments in medical technology, regulatory approvals and extensive regulatory oversight by the FDA or other regulatory bodies, unfavorable media coverage related to our products or related procedures, reimbursement decisions by private or government payors, physician adoption and recommendations of procedures utilizing our products and other factors detailed from time to time in the reports Apollo files with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2017 and its Form 10-Q for the three months ended March 31, 2018. Copies of reports filed with the SEC are posted on Apollo’s website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.